Immunomodulators in the Treatment of Nasal Polyposis

Ashleigh A. Halderman, Andrew P Lane

Research output: Contribution to journalArticle

Abstract

The inflammatory mechanisms that contribute to chronic rhinosinusitis with nasal polyps (CRSwNP) are complex. In the past, medical options for treating CRSwNP have been limited. Emerging classes of immunomodulators such as omalizumab, anti-leukotrienes, anti-IL-4, anti-IL-5, and recognition of the modulating effects of macrolides have shown promising results in the treatment of CRSwNP. Ultimately, large randomized controlled trials are necessary to establish the efficacy of these medications but for now, the area of medical immunomodulators remains an exciting frontier.

Original languageEnglish (US)
Pages (from-to)103-113
Number of pages11
JournalAdvances in Oto-Rhino-Laryngology
Volume79
DOIs
StatePublished - 2016

Fingerprint

Nasal Polyps
Immunologic Factors
Nose
Leukotrienes
Interleukin-5
Macrolides
Interleukin-4
Randomized Controlled Trials

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Medicine(all)

Cite this

Immunomodulators in the Treatment of Nasal Polyposis. / Halderman, Ashleigh A.; Lane, Andrew P.

In: Advances in Oto-Rhino-Laryngology, Vol. 79, 2016, p. 103-113.

Research output: Contribution to journalArticle

@article{42bd6d037e9b45198e6830888413aac6,
title = "Immunomodulators in the Treatment of Nasal Polyposis",
abstract = "The inflammatory mechanisms that contribute to chronic rhinosinusitis with nasal polyps (CRSwNP) are complex. In the past, medical options for treating CRSwNP have been limited. Emerging classes of immunomodulators such as omalizumab, anti-leukotrienes, anti-IL-4, anti-IL-5, and recognition of the modulating effects of macrolides have shown promising results in the treatment of CRSwNP. Ultimately, large randomized controlled trials are necessary to establish the efficacy of these medications but for now, the area of medical immunomodulators remains an exciting frontier.",
author = "Halderman, {Ashleigh A.} and Lane, {Andrew P}",
year = "2016",
doi = "10.1159/000445141",
language = "English (US)",
volume = "79",
pages = "103--113",
journal = "Advances in Oto-Rhino-Laryngology",
issn = "0065-3071",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Immunomodulators in the Treatment of Nasal Polyposis

AU - Halderman, Ashleigh A.

AU - Lane, Andrew P

PY - 2016

Y1 - 2016

N2 - The inflammatory mechanisms that contribute to chronic rhinosinusitis with nasal polyps (CRSwNP) are complex. In the past, medical options for treating CRSwNP have been limited. Emerging classes of immunomodulators such as omalizumab, anti-leukotrienes, anti-IL-4, anti-IL-5, and recognition of the modulating effects of macrolides have shown promising results in the treatment of CRSwNP. Ultimately, large randomized controlled trials are necessary to establish the efficacy of these medications but for now, the area of medical immunomodulators remains an exciting frontier.

AB - The inflammatory mechanisms that contribute to chronic rhinosinusitis with nasal polyps (CRSwNP) are complex. In the past, medical options for treating CRSwNP have been limited. Emerging classes of immunomodulators such as omalizumab, anti-leukotrienes, anti-IL-4, anti-IL-5, and recognition of the modulating effects of macrolides have shown promising results in the treatment of CRSwNP. Ultimately, large randomized controlled trials are necessary to establish the efficacy of these medications but for now, the area of medical immunomodulators remains an exciting frontier.

UR - http://www.scopus.com/inward/record.url?scp=84992154191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992154191&partnerID=8YFLogxK

U2 - 10.1159/000445141

DO - 10.1159/000445141

M3 - Article

VL - 79

SP - 103

EP - 113

JO - Advances in Oto-Rhino-Laryngology

JF - Advances in Oto-Rhino-Laryngology

SN - 0065-3071

ER -